A multi-level intervention to eliminate hepatitis C from the Region of Southern Denmark : the C-Free-South project
© 2022. The Author(s)..
Denmark has signed the WHO strategy to eliminate hepatitis C virus (HCV). In the absence of a national strategy for elimination, a local action plan was developed in the Region of Southern Denmark (RSD). The aim of the strategy is to diagnose 90% of HCV-infected persons and treat 80% of those diagnosed by 2025. The strategy was developed by reviewing Danish data on HCV epidemiology and drug use to identify key populations for screening, linkage to care, and treatment. Based on available published data from 2016, an estimated 3028 persons in the RSD were HCV-RNA positive (population prevalence 0.21%). Of these, 1002 were attending clinical care, 1299 were diagnosed but not in clinical care, and 727 were undiagnosed. Three different interventions targeting the HCV-infected population and two interventions for HCV surveillance are planned to achieve elimination. The "C-Free-South" strategy aims to eliminate HCV in our region by identifying (90%) and treating (80%) of infected persons by the end of 2025, 5 years earlier than the WHO elimination target date.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
BMC infectious diseases - 22(2022), 1 vom: 01. März, Seite 202 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dröse, Sandra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 03.03.2022 Date Revised 10.03.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12879-022-07196-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337636737 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337636737 | ||
| 003 | DE-627 | ||
| 005 | 20231225234854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12879-022-07196-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337636737 | ||
| 035 | |a (NLM)35232372 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dröse, Sandra |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A multi-level intervention to eliminate hepatitis C from the Region of Southern Denmark |b the C-Free-South project |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2022 | ||
| 500 | |a Date Revised 10.03.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Denmark has signed the WHO strategy to eliminate hepatitis C virus (HCV). In the absence of a national strategy for elimination, a local action plan was developed in the Region of Southern Denmark (RSD). The aim of the strategy is to diagnose 90% of HCV-infected persons and treat 80% of those diagnosed by 2025. The strategy was developed by reviewing Danish data on HCV epidemiology and drug use to identify key populations for screening, linkage to care, and treatment. Based on available published data from 2016, an estimated 3028 persons in the RSD were HCV-RNA positive (population prevalence 0.21%). Of these, 1002 were attending clinical care, 1299 were diagnosed but not in clinical care, and 727 were undiagnosed. Three different interventions targeting the HCV-infected population and two interventions for HCV surveillance are planned to achieve elimination. The "C-Free-South" strategy aims to eliminate HCV in our region by identifying (90%) and treating (80%) of infected persons by the end of 2025, 5 years earlier than the WHO elimination target date | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Elimination | |
| 650 | 4 | |a Epidemiology | |
| 650 | 4 | |a Hepatitis C virus | |
| 650 | 4 | |a Interventions | |
| 650 | 4 | |a Testing | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Hepatitis C Antibodies |2 NLM | |
| 700 | 1 | |a Øvrehus, Anne Lindebo Holm |e verfasserin |4 aut | |
| 700 | 1 | |a Holm, Dorte Kinggaard |e verfasserin |4 aut | |
| 700 | 1 | |a Madsen, Lone Wulff |e verfasserin |4 aut | |
| 700 | 1 | |a Mössner, Belinda Klemmensen |e verfasserin |4 aut | |
| 700 | 1 | |a Søholm, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Hansen, Janne Fuglsang |e verfasserin |4 aut | |
| 700 | 1 | |a Røge, Birgit Thorup |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Peer Brehm |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC infectious diseases |d 2001 |g 22(2022), 1 vom: 01. März, Seite 202 |w (DE-627)NLM11120089X |x 1471-2334 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:1 |g day:01 |g month:03 |g pages:202 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12879-022-07196-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 1 |b 01 |c 03 |h 202 | ||